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a b s t r a c t
Gene therapy andvaccines are rapidly developingﬁeld inwhich recombinant nucleic acids are introduced
in mammalian cells for enhancement, restoration, initiation or silencing biochemical function. Beside
simplicity in manipulation and rapid manufacture process, plasmid DNA-based vaccines have inherent
features thatmake thempromisingvaccine candidates in avarietyofdiseases. Thispresent review focuses
on the safety concern of the genetic elements of plasmid such as propagation and expression units aseywords:
NA vaccine
ost genome
lasmid DNA
esistance marker
well as their host genome for the production of recombinant plasmid DNA. The highlighted issues will
be beneﬁcial in characterizing and manufacturing plasmid DNA for save clinical use. Manipulation of
regulatory units of plasmid will have impact towards addressing the safety concerns raised in human
vaccine applications. The gene revolutionwith plasmidDNAby alteration of their plasmid andproduction
host genetics will be promising for safe delivery and obtaining efﬁcient outcomes.ynthetic vector © 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
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. Introduction
To date, over 1626 gene therapy and vaccines has been com-
leted phase I/II clinical trial worldwide [1,2]. Both viral and
on-viral vectors can aid in therapeutic genes towards the targeted
ell nucleus. However, the occurrences of unfortunate adverse
vents have slowed the clinical trial progress and more investi-
ation on viral vector behavior should be reﬁned [1,3,4]. Non-viral
ene therapy has emerged as an alternative for viral gene ther-
py to introduce nucleic acid in mammalian cells for enhancement,
estoration, initiation or silencing biochemical function [5–7]. Fur-
hermore, plasmid DNA has rapid manufacturing timeline [8].
Most  plasmids used for vaccination purposes share the basic
ttributes of vectors developed for optimal expression in eukary-
tic cells (Fig. 1). The essential features for plasmid DNA vaccines
onsist of (a) an origin of replication allowing for high yields of
roduction in bacteria; (b) an antibiotic resistance gene to con-
er antibiotic-selected growth during bacterial culture; (c) a strong
nhancer/promoter for transgene expression in mammalian cells;
nd (d) a polyadenylation termination sequence for mRNA tran-
cript stabilization.
.  Factors associated to plasmid propagation unit
.1.  Replication region
The  replication region for plasmid DNA construct is very impor-
ant as it provides an appropriate framework for production and
rocess development. Plasmid origin is a minimal cis-acting region
or autonomous plasmid replication, a requisite for plasmid-host
ncoded protein interaction [9]. Plasmid copy number can be inﬂu-
nced by the efﬁciency of replication origin and the percentage of
ompleted replication cycles [10]..1.1. Avoidance of mammalian sequence in replication region
Traditionally, engineered plasmids are void of functional repli-
ation region for mammalian cells [11]. Normally, replication
egion derived from prokaryotic cell (such as ColE1, pMB1, R6K)
ig. 1. Schematic drawing of a bacterium with plasmid. The essential components
f  a plasmid DNA vector include a transcriptional unit, which consists of a viral
romoter  (i.e. simian virus 40, cytomegalovirus), intron, signal peptide (SP), an insert
or transgene, and transcription termination sequences (Poly A). The other essential
omponents include a bacterial origin of replication and antibiotic resistance gene,
llowing for growth and selection in bacteria. . . . .  .  .  .  .  .  . . . .  .  .  .  .  .  . . .  . .  .  .  .  . . . . . .  .  .  .  . . . . . . .  .  .  . . . . . .  .  . .  . .  .  .  . .  .  .  . .  . . . .  . .  .  .  . . 5919
drives high yields of production in bacterial host [10,12]. Plas-
mid with additional replication region for mammalian functionality
allows prolonged persistence and expression of the transgene but
also has a downside. Its replication in the mammalian host causes
chromosomal DNA integration [13]. The genome integration of
introduced plasmid DNA in an animal may be, phenotypically
mutagenic if the integration event disrupted the cellular gene, or
potentially carcinogenic if the integration event inactivated a reg-
ulatory gene for cell division or activated oncogenes [11].
Integration may  occur either randomly or as a result of homolo-
gous recombination. Homologous recombination is possible during
parallel replication of the host and plasmid DNAs or when large
(>600 bp) regions of homology between host and plasmid are in
close proximity [11]. A study conducted by Shimizu et al. on plas-
mids carrying the mammalian replication origin sequences from
Chinese-hamster dihydrofolate reductase (DHFR) and human c-
Myc  loci evidenced chromosomal integration activity [14]. The
integration targeted cis-acting matrix attachment region (MAR),
which functions in genome replication in mammalian cells [15].
Therefore, mammalian sequence associated to mammalian gene
expression and replication should be avoided, whilst keeping
preference to sequences from prokaryotic origin for engineering
plasmid backbone [16].
2.1.2.  Mutating replication region
The presence of nucleotide sequence of bacterial gene product,
such as unmethylated cytosine–phosphate–guanine (CpG) motif
can adversely affect a mammalian host receiving plasmid DNA.
These sequences may  induce immune responses [17,18], as well
as possible gene silencing targeted against the plasmids [19,20].
Through proper designing and generating DNA coding regions, the
“cg” sequence (CpGs) could be eliminated without changing the
amino acid sequence [21]. Another aspect involves the removal of
excessive, non-functional DNA backbone sequences in the plasmid.
RNAII is the primer for ColE1-derived plasmid replication pro-
cess and it is inhibited by RNAI [22,23]. A point mutation that alters
the consensus–10 element in the RNAII promoter from TAATCT to
TAATAT in a ColE1-derived plasmid named pXPM [24], has been
predicted to increase the rate of RNAII transcription. An increase
in the RNAII to RNAI ratio would increase the frequency of DNA
replication initiation events. However, precautionary modiﬁcation
needed to prevent exorbitant RNAII elevation, which could lead to
“runaway” plasmid replication [21].
2.1.3. Narrow host range replication region
Usually, DNA therapy involves injection of milligram quantities
of plasmid. Plasmid with narrow host-range will have less proba-
bility of spread to patient’s microﬂora during therapy. Replication
region dependent on chromosomally encoded factors restricts the
replication process to a single host strain. The pCOR vectors based
on trans-complementation has been engineered to increase safety
in terms of plasmid loss and dissemination [25]. The pCOR vector
backbone consists of R6K conditional origin which requires the
R6K initiator protein to be functional. This plasmid can uniquely
replicate in -producing bacteria, thus restricting their produc-
tion host range. Hence, only prokaryotic and narrow host range
replication should be present in the plasmid backbone to avoid
any chromosomal homologies. It is also critically important for
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ector system to replicate their genomes autonomously as extra-
hromosomal elements to avoid undesirable integration [26].
.1.4.  Minimized plasmid
Sequences  in replication origin (backbone) essential for bacte-
ial production but not for therapeutic expression in mammalian
ells may  cause complications in patient, for example activation
f cryptic expression signals [27]. Contaminating nucleic acids
equences coding for a recombinase (e.g. PhiC31), and/or restriction
ndonuclease (e.g. I-Sce 1), are undesirable because the chance of
eing transferred into the recipient cells and expressed during the
ransformation process is the most likely possibility. The expres-
ion product has damaging capability on recipient’s genomic DNA
ncluding chromosomal aberrations [28]. One approach is to gener-
te minicircle that are devoid of the replication origin and selectable
arker, using integrase-mediated intramolecular recombination
echnique for expressing high and persistence levels of transgene
n vivo [29]. Through minicircle technology, undesirable endonu-
lease and recombinase genes can be avoided and greatly reduced
mounts of l-arabinose to induce DNA editing enzymes allowing
aking clinical grade of minicircle DNA vector more easily and cost
ffective [30].
.2.  Resistance gene and its avoidance for selection
Antibiotic resistance markers are the most commonly utilized to
nsure stable inheritance in plasmid production. One of the major
oncerns associated with in vivo application is the possible uptake
f therapeutic gene or resistant marker by patient’s enteric bacteria
10]. The existence of these antibiotic markers in plasmid backbone
s discouraged by regulatory agencies due to (a) the potential trans-
it  of antibiotic resistance genes to patient’s microﬂora (b) the
ossibility of activation and transcription of the genes upon cel-
ular incorporation into the human genome and (c) concern with
-lactam antibiotics which can cause allergic reaction in some peo-
le [16,31,32]. Because of these concerns, FDA has forbidden the
sage of ampicillin and -lactam antibiotics during plasmid pro-
uction for human use [33]. Aminoglycoside such as kanamycin
nd neomycin are currently preferred, since they are rarely used in
linics and have low incidence effects of ototoxicity and nephro-
oxicity [34]. Due to this safety concern, various selection systems
ased on plasmid–host interaction have been developed. Recent
atents and patents application on non-antibiotic plasmid marker
n plasmid DNA production are listed in Table 1 [35–41].
.2.1. Auxotrophy complementation
In  these systems, an essential gene is maintained in the plas-
id backbone. Such plasmids can be selected and propagated in
acterial host strains that contain a corresponding chromosomal
eletion or suppressible mutation of the essential gene [10]. In
hese plasmid systems, antibiotic resistance markers can be cir-
umvented and plasmid sizes are often very small.
For example, Porter et al., have developed genetically engi-
eered bacteria by deleting the essential single-strand binding
rotein (SSB) gene responsible for replication of the Escherichia coli
hromosome and its single-stranded DNA phage, and instead com-
lementing the ssb gene on a plasmid [42]. Plasmidless bacteria
o not accumulate even after culture under non-selective con-
ition. In fact, by using plasmid-displacement technique, other
sb-containing plasmids can be readily introduced into this E. coli
train.
As another example, the pCOR vector has been totally
edesigned to increase biosafety in terms of dissemination and
election during therapy and production [25]. The pCOR vector
ackbone consists of R6K conditional  origin which requires cis or
rans-acting R6K initiator protein to be functional. This plasmid (2012) 5914– 5920
can  only replicate in -producing bacteria which restrictive their
production host range. Instead of harboring antibiotic resistance
gene, a bacterial suppressor tRNA has been used as selectable
marker to suppress a host chromosomal argE gene mutation,
allowing for growth in minimal media lacking arginine. However,
additional genes are required to be placed on plasmid in this sys-
tem.
2.2.2. Repressor titration
In  this system, the repressor titration was manipulated and
affects a plasmid selection pressure [10]. A multicopy plasmid
containing the same operator sequence was  used to derepresses
a negatively-regulated chromosomal operator/promoter system
controlling a conditionally essential gene. Under normal condi-
tions, a repressor protein binds to the chromosomal operator and
prevents transcription. The repressor is released when it binds to
its inducer, which is often the substrate of the gene under control.
Conversely, the present of molar excess operator sequence on a
multicopy plasmid will titrate the repressor from the chromosomal
operator which allows transcription to take place.
For example, Cranenburgh et al. have constructed two novel E.
coli strains (DH1lacdapD and DH1lacP2dapD) containing an ectopic
copy of a dapD essential chromosomal gene, where expression
driven under the control of the lac operator/promoter [43]. Three
copies of the operator on the plasmid titrate the lac repressor,
allowing expression of the dapD gene. However, dapD expression
is inhibited and the E. coli cell dies in the absence of the multicopy
plasmid. The advantage of such system is small size plasmid and
elimination of antibiotic resistance gene.
Another system that employs plasmid-mediated repressor titra-
tion was  described in which the recombinant plasmid contained
lacO while the host genome contained a kanamycin resistance gene
under the control of the lacO promoter [44]. This E. coli strains could
only propagate in kanamycin-containing media if host-encoded
LacI repressor molecules were successfully titrated by plasmid-
based lacO. Thus, this strain allows plasmid selection pressure
without incorporation of antibiotic resistance genes in the plas-
mid propagation unit; they required only lacO and an origin of
replication for propagation purposes, which give advantages for
use as gene therapy vectors. However, a potential disadvantage of
this system is complication between promoter and operator sites
which have been shown to cause interference in DNA replication,
and antibiotic is still needed in the culture broth [45].
2.2.3. ‘Toxin–antitoxin’ protein selections
Toxin–antitoxin (TA) system comprises of two essential ele-
ments; a biologically active protein molecule as ‘toxin’, and the
corresponding inhibitor as ‘antitoxin’. In this scheme, both toxin
and antitoxin will be expressed at low levels upon transformation
of plasmid containing a functional TA operon into a bacterial cell,
and form a toxin–antitoxin complex. Due to complex formation,
the bacteria cell is protected against the action of the toxin. The
toxin–antitoxin complex also acts as a repressor to the transcrip-
tion of the TA operon. At least, one copy of the plasmid retained
in the bacteria cell will stabilise the situation. However, once the
plasmid is lost during cell division, the system will be activated. The
labile antitoxin is constantly degraded by a speciﬁc protease in the
cell and freed the toxin. As a result, the toxin can attack its target in
plasmidless cells thus inhibiting cell growth and ultimately killing
the cell [46].
As  an example, F-plasmid ccd antidote-poison operon was mod-
iﬁed for this system. The ccd operon of the F plasmid encodes CcdB,
a toxin targeting the essential gyrase of E. coli, and CcdA, the unsta-
ble antidote that interacts with CcdB to neutralize its toxicity; this
scheme allowed plasmid stabilization by killing newborn bacteria
that have lost a plasmid copy at cell division [47]. This system does
R. Ismail et al. / Vaccine 30 (2012) 5914– 5920 5917
Table 1
Recent patents and patents application on non-antibiotic plasmid marker in plasmid DNA production.
Reference number/year Title Assignee Selection system
US20100003738 (2010) Plasmid curing. Berliner and Associates Toxin–antitoxin/RNA based
US20100028378 (2010) Toxin–antitoxin system and applications thereof. Newsouth Innovations Pty. Ltd. Toxin–antitoxin
USPat7611883 (2009) Plasmid maintenance. Cobra Biologics Ltd. Repressor titration
WO2008153733  (2008) Vectors and methods for genetic immunization. Nature Technology Corp. RNA based
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cUSPat712570  (2007) Plasmid maintenance system for antigen delivery. 
WO2006029985 (2006) Host-vector system for antibiotic-free ColE1 plasmid
USPat6872547  (2005) Functional balanced-lethal host-vector systems. 
nclude a protein based selection marker (CcdB) and has not been
valuated in large scale plasmid production.
.2.4. RNA based selectable marker
This selection system utilized the endogenous RNAI/RNAII
ntisense regulators of the replication origin [10]. Bacterial chro-
osome in this system was designed to contain an RNAII sequence
ithin the untranslated region of the mRNA. During plasmid
vailability, the expressed RNAI repressor binds both the plasmid
ncoded RNAII and also chromosomally expressed RNAII sequence
nd formed RNAI:RNAII complex which suppresses the translation
f the chromosomal gene through RNA–RNA antisense regulation.
he regulated gene can be a resistance marker, repressor gene or a
oxic/lethal gene [32,40,43,48].
Recently,  a new RNA based antibiotic-free selection system
as been reported [32]. The expression of SacB (Bacillus subtilis
evansucrase), a counter-selectable marker was  designed to be
ey component since cells containing SacB were killed in the
resence of sucrose. The SacB gene driven by RNA-IN promoter
as integrated into the chromosome of DH5, whilst plasmid
as incorporated with 150 bp antisense RNA-OUT. In the pres-
nce of RNA-OUT antisense regulator, RNA translation of SacB will
e silenced and eventually allows plasmid selection in sucrose-
ontaining media [32].
Bacterial strain has been modiﬁed to allow suppression of
rowth essential gene (murA) by repressor protein (tetR) through
NA–RNA antisense reaction [48]. In this system, the plasmid’s
eplicational inhibitor RNA I could silence the tetR expression. For
his reason, tetR will be turned down and murA expressed for host
ropagation during the presence of plasmid.
. Factors associated to plasmid borne eukaryotic
xpression
The plasmid DNA transcription unit consists of essential com-
onents; promoter, intron, signal sequence and polyA, for high
xpression levels and targeting of the therapeutic element in the
ammalian cells (Fig. 1).
.1. Synthetic vector
.1.1.  Manipulation of promoter
Gene  promoters contain arrays of regulatory elements to which
ranscriptional factors bind and interact with each other to regulate
ranscription. Traditionally, promoters and enhancer regions are
erived from pathogenic viruses such as cytomegalovirus (CMV),
imian virus 40 (SV40), or murine leukaemia virus. Until now,
lasmid DNA promoter from CMV  is widely used and has been
n clinical trials due to its capability to adapt in an array of tis-
ues and animal models [49]. Unfortunately, a new CMV  chimera
ight be formed by the recombination between CMV  promoterrom plasmid vaccine and naturally exist wild-type CMV  inside
he vaccinated person [10]. In fact, rates of integration or recom-
ination can be inﬂuenced by fragments of DNA as short as seven
onstant base pairs [50].University of Maryland Toxin–antitoxin
agation. Boehringer Ingelheim RNA based
Washington University Auxotrophy complementation
In conjunction with oncogenesis and mutagenesis risk, highly
inter-species-conserved sequences such as housekeeping genes
encoding the phosphoglycerate kinase (pgk) and ataxia telangiecta-
sia ATM/E14 should be avoided in promoters and enhancer regions
[51,52]. Novel synthetic promoters with less risky could be design
and selected through bioinformatic tools. Low homology with host
sequences could be achieved by using codon optimization software
such as OPTIMIZER or gene design software [53,54].
Synthetic promoter also can be generated using ‘fusing tech-
nique’. One or two enhancer elements fused to a heterologous
promoter sequence. A few investigators have extended this
approach by composing various combination of many regulatory
sequences [55,56]. For example, Li et al. randomly assembled
muscle-speciﬁc elements (E-box, MEF-2, TEF-1, and SRE sites) from
four different muscle-speciﬁc promoters [56]. These novel pro-
moter sequences were screened and one sequence was  found
having 8-fold higher transcriptional activity comparing to innate
muscle promoters.
Novel  synthetic promoter sequences also can be created by
either random ligation of multiple transcription factor binding sites
or by DNA shufﬂing [57]. Transcription factor fragments are ligated
randomly and then inserted into a reporter plasmid for veriﬁcation.
Li et al. showed that activation of serum activation element (SRE
activation binding site) at the CMV/SkA promoter region using SRF
co-expression technique not only enhance the transgene expres-
sion, but also maintained the expression up to 21 days [58]. Using
DNA shufﬂing technique, Wright et al. have created chimeric pro-
moter originated from two human and two nonhuman primate
strains of CMV  [49]. Screening assays indicated 2-fold increased
reporter gene expression compared to wild-type promoters.
Although an initial screen for activity can be done in vitro, in vivo
attempt would be challenging. Only with appropriate screen in
place, novel artiﬁcial promoter that outperforms existing endoge-
nous sequence, in terms of both safety levels and duration of
expression can be identiﬁed.
3.1.2.  Intron manipulation
Transgene  expression is generally higher if introns are included
in the vector backbone downstream of the promoter. Intron, as
part of an mRNA leader augments promoter effect for expression
of therapeutic gene in vivo [59,60]. Usually, plasmid expression for
mammalian cells uses intron A from human CMV  [61]. Here too,
synthetic intron can be designated with the aid of bioinformatics
to avoid existing sequences in CMV-infected person.
Synthetic intron can enhance mRNA production. Short synthetic
intron with efﬁcient spliceable-site can expedite mature mRNA
production and transportation from nucleus to the cytoplasm [62].
Therefore, vectors harboring it stand a better chance to overcome
mRNA accumulation barrier, in comparison to vectors with endoge-
nous introns. For example, synthetic intron, Ivs8 has been proven
safe without causing any mutagenesis to the host [63,64]. A syn-
thetic intron consisting a polynucleotide fragment splice site of a
sarcoplasmic/endoplasmic reticulum calcium ATPase gene and a
fragment contains at least a portion of a 5′UTR of a casein gene, can
increase RNA transport and stability [65].
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.1.3. Modiﬁcation of signal sequence
Signal sequence facilitates extra-cellular secretion of the vac-
ine peptide. This 15–30 amino acids encoded signal placed
pstream of the therapeutic gene often derived from human
-1-antichymotrypsin precursor (ACT) and tissue plasminogen
ctivator (TPA) [66,67]. However, immunological cross-reaction
an happen when signal peptides (SP) fuse to immunogen, espe-
ially when those peptides are administered alone as a gene vaccine
hich in turn activates protective immunity against microbial
athogen [68].
Prior  screening using statistical methods like the Hidden Markov
odel should be considered to avoid undesired immune responses
rom signal peptide. This modelling is used as prediction methods
o generate artiﬁcial SP sequences by creating a multiple alignment
f a comprehensive set of known human secretory signal peptides
69].
.1.4. Modiﬁcation of polyadenylation signal
This termination signal is positioned downstream of the thera-
eutic gene and often derived from bovine growth hormone, SV40
r -globin genes. Constructions of hybrid polyA signal from sta-
le eukaryotic mRNA was further improved and boosts the protein
xpression in mammalian cells [70]. Such a strategy could be uti-
ized to DNA vaccine development to create more efﬁciency in
uclear export, translation and mRNA stability.
.2. Modular cloning vector
Vectors  can be modularly cloned to provide backbone with
ocking points for gene expression and analytic purposes. This opti-
ized vector is useful to diminish the frequency of manipulation
equires for assembling fragments or transgene into de novo DNA
onstruct. Ideally, module vector contains an arrangement of at
east one multiple cloning site (MCS) and variable sets of unique
estriction sites. The invention of PE3 vector comprises a Promoter
odule, an Expression module, and a 3′ Regulatory module. This
odular architecture allows one to place or remove domain mod-
les without interfere the DNA integrity of essential elements in
E3 vector [71].
.  Factors associated with production host
Plasmid manufacturing area for gene therapy has emerged.
owever, further advancement is needed for scaling up in order
o fulﬁll commercial viability, especially factors associated with
roduction host; strain improvement, genome modiﬁcation, fer-
entation and puriﬁcation [72–74]. The characteristics of the
icrobial host also give effect to the quality of the puriﬁed pDNA
n production [75].
.1.  Use of gram-positive organism production
Although not so efﬁcient, gram-positive bacteria such as Lac-
ococcus lactis, produces neither endotoxin nor biogenic amines
hich eliminate the dependency on cGMP-certiﬁable LPS-removal
rocess during plasmid production [76]. A comparison study
etween food grade L. lactis system to a traditional one in E. coli
sing identical expression unit encoding the gp120 of HIV-1
roduced comparable vaccine component and humoral immune
esponse. Common L. lactis research strains are also genetically
ree of antibiotic resistance gene, potent and narrow host-range
rophages [77].For  clinical trial, large-scale production is needed, often in about
housand litres. The fermentation medium must sustain a high level
roduction of biomass and plasmid DNA. Improved vector design
nd host of production will be critical to ensure safety, efﬁcacy and (2012) 5914– 5920
cost effective manufacture of these new generation vaccines. Fur-
thermore, it is not simple to switch from E. coli to gram positive
bacterium in pDNA productions.
4.2.  Deleted endotoxin gene genome
E. coli is undoubtedly the microbe of choice for optimal produc-
tion and utilization, but as a gram-negative bacterium, it contains
highly immunogenic endotoxin or lipopolysaccharides (LPS) in its
outer membrane which can cause ‘endotoxic/septic shock’ to the
patient [78]. Although chromatography technique do exist that can
exclude the LPS from pDNA, these molecules can be co-puriﬁed by
the ion exchange puriﬁcation approach [79]. The usage of non-ionic
detergent followed by size exclusion chromatography (SEC) tech-
niques is simple and scalable, but hampered by low supercoiled
plasmid recovery [80].
An  approach to reduce endotoxin level is by deleting LPS gene in
the bacterial genome. Several genes involved in LPS synthesis in E.
coli such as msbB are not essential, and the cell can tolerate deletion
or loss of function of these speciﬁc genes [81]. In many instances
such deletions can reduce endotoxin level, even when grown in rich
undeﬁned media [74].
4.3.  Smaller host genome
For  efﬁciency reasons, E. coli is the most extensively studied vec-
tor, modiﬁed for high copy number replication, process production
and scaling-up conditions [34].
Bacterial genome is genetically engineered to be 2–14% smaller
than its native parent strain [73]. A few genes and DNA sequences
that are not required for cell survival and unnecessary protein
production in culture, can be deleted using multiple-deletion
series (MDS) technique [82]. Smaller genome offers advantage in
terms of resource consumption, speed-up production, and sim-
pliﬁed puriﬁcation process. Some bacterial genome is associated
with instabilities such as recombinogenic and cryptic virulence
genes [82]. SbcCD protein from sbcC and sbcD genes recognizes
and cleaves hairpin of shRNA plasmid [83]. By using this tech-
nique, a product that cannot be produce before, due to native
protein interference from host can now be produced in ample
quantities. Purer, safe and less contaminated products can be
made.
5. Conclusions and future outlook
Safety concerns continuously arise from regulatory agency. The
rapid development and usage of recombinant plasmid DNA in
gene therapy and vaccines raise concerns related to safety, long-
term adverse effect, integration, dissemination and toxicity of
plasmid DNA during clinical trial. Through plasmid DNA design
optimization and appropriate host strain modiﬁcation, improve-
ments can be achieved in plasmid safety and also production.
Bioinformatic tools such as BLAST, OPTIMIZER can be utilized to
develop robust plasmid’s genetic elements without compromising
safety.
Some of the raised concerns are in the solving processes with the
development of better plasmid performance. Future industrial scale
minicircle production will facilitate progress in clinical trials. Novel
synthetic combination promoter/enhancer will advance plasmid’s
tissue speciﬁcity and safety. In order to minimize inﬂammation to
the patient, there is a crucial need for a clean lineage of CpG free
and antibiotic marker free plasmid. In addition, the manufacturing
of plasmid DNA should boost efﬁciency to be cost-effective, whilst
maintaining efforts to keep endotoxin at low level.
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